New information for HCPs: A new indirect treatment comparison presented at the #EASD2026 annual meeting compared the highest dose of our dual GIP/GLP-1 obesity medicine with the highest dose of another obesity medicine. This analysis reflects our commitment to providing clinicians with evidence to support treatment decisions. Read more at the link in our bio.